Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Inherited Metabolic Diseases of the Nervous System, Hepatolenticular Degeneration (Wilson Disease)
Adams & Victors Principles of Neurology, Chp 37, pg 982, Ropper, A.H.,et al, 2014
Wilson Disease: Description of 282 Patients Evaluated Over 3 Decades
Medicine 86:112-121, Taly,A.B., et al, 2007
Development of Neurologic Symptoms in a Patient with Asymptomatic Wilson's Disease Treated with Penicillamine
Arch Neurol 51:304-305, Brewer,G.J.,et al, 1994
Worsening of Neurologic Syndrome in Patients with Wilson's Disease with Initial Penicillamine Therapy
Arch Neurol 44:490-493, Brewer,G.J.,et al, 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Wilson Disease
Medicine 71:139-164, Brewer,G.J.&Yuzbasiyan-Gurkan,V., 1992
Wilson Disease:Clinical Presentation, Treatment, and Survival
Ann Int Med 115:720-726, Stremmel,W.,et al, 1991
Wilson's Disease
In Oxford Textbook of Clin Hepatology, Oxford Univ Press, Vol 2, Ch 20. 1, p. 947, Sternlieb,I.&Scheinberg,I.H., 1991
The Pathophysiology of Penicillamine-Induced Myasthenia Gravis
Ann Neurol 20:740-744, Kuncl,R.W.,et al, 1986
Penicillamine-Induced Myositis
Am J Med 77:719-722, Halla,J.T.,et al, 1984
Successful Treatment of Inorganic Mercury Neurotoxicity with N-acetyl-penicillamine Despite an Adverse Reaction
Neurol 30:1000-1001, Markowitz,L.,et al, 1980
Diagnosis of Treatable Wilson's Disease
NEJM 298:1347, Cartwright,G.E., 1978
Cholelithiasis and Wilson Disease
J Pediatr 2:210-213, Rosenfield,N.,et al, 1978
Reversible Forms of Motor Neuron-Disease:Lead"Neuropathy"
Neurol 22:446, Boothby,J., 1972